Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin

Early Intervention in Psychiatry

Volumn 12, Issue 1, 2018, Pages 45-54

  Quinn, Amelia L ^a,b   Dean, Olivia M ^c,d,e   Davey, Christopher G ^a,b,f   Kerr, Melissa ^a,b   Harrigan, Susy M ^a,b   Cotton, Sue M ^a,b   Chanen, Andrew M ^a,b,f   Dodd, Seetal ^c,d,e   Ratheesh, Aswin ^a,b,f   Amminger, G Paul ^a,b   Phelan, Mark ^a,b,f   Williams, Amber ^a,b   Mackinnon, Andrew ^a,b   Giorlando, Francesco ^d,f   Baird, Shelley ^a,b   Rice, Simon ^a,b,f   O'Shea, Melissa ^e   Schäfer, Miriam R ^a,b   Mullen, Edward ^a,b,f   Hetrick, Sarah ^a,b   McGorry, Patrick ^a,b   Berk, Michael ^a,b,c,d,e   more..

^a THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e BARWON HEALTH   (Australia)

^f NorthWestern Mental Health   (Australia)

Author keywords

aspirin; depression; inflammation; rosuvastatin; youth

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CREATINE KINASE; CYANOCOBALAMIN; FOLIC ACID; GLUCOSE; PLACEBO; ROSUVASTATIN; THYROTROPIN; UREA; BIOLOGICAL MARKER; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICATION COMPLIANCE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OCCUPATIONAL HEALTH; OXIDATIVE STRESS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL INTERACTION; SUICIDAL IDEATION; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UREA BLOOD LEVEL; VITAMIN BLOOD LEVEL; AUSTRALIA; BLOOD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; AUSTRALIA; BIOMARKERS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; ROSUVASTATIN CALCIUM; YOUNG ADULT;

EID: 84948799283     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12280     Document Type: Article

References (71)

1. Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clin Psychol Rev 1998; 18: 765–794.
2. Twenge JM, Gentile B, DeWall CN, Ma D, Lacefield K, Schurtz DR. Birth cohort increases in psychopathology among young Americans, 1938-2007: a cross-temporal meta-analysis of the MMPI. Clin Psychol Rev 2010; 30: 145–154.
3. Weissman MM, Wolk S, Goldstein RB et al. Depressed adolescents grown up. J Am Med Assoc 1999; 281: 1707–1713.
4. Fergusson DM, Woodward LJ. Mental health, educational, and social role outcomes of adolescents with depression. Arch Gen Psychiatry 2002; 59: 225–231.
5. Birmaher B, Williamson DE, Dahl RE et al. Clinical presentation and course of depression in youth: does onset in childhood differ from onset in adolescence? J Am Acad Child Adolesc Psychiatry 2004; 43: 64–70.
6. Fombonne E, Wostear G, Cooper V, Harrington R, Rutter M. The Maudsley long-term follow-up of child and adolescent depression: 1. Psychiatric outcomes in adulthood. Br J Psychiatry. 2001; 179: 210–217.
7. Hirschfield RMA. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000; 61 (Suppl. 6): 4–6.
8. Haase J, Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression – a central role for the serotonin transporter? Pharmacol Ther 2015; 147: 1–11.
9. Trivedi M, Rush AJ, Wisniewski AA et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28–40.
10. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804–817.
11. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res 1995; 674: 82–90.
12. Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 2013; 150: 736–744.
13. Gabbay V, Klein RG, Guttman LE et al. A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression. J Child Adolesc Psychopharmacol 2009; 19: 423–430.
14. Pasco JA, Nicholson GC, Williams LJ et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry 2010; 197: 372–377.
15. Kalivas PW, O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008; 33: 166–180.
16. Basterzi AD, Aydemir C, Kisa C et al. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005; 20: 473–476.
17. Tynan RJ, Weidenhofer J, Hinwood M, Cairns MJ, Day TA, Walker FR. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun 2012; 26: 469–479.
18. Dhami KS, Churchward MA, Baker GB, Todd KG. Fluoxetine and citalopram decrease microglial release of glutamate and d-serine to promote cortical neuronal viability following ischemic insult. Mol Cell Neurosci. 2013; 56: 365–374.
19. Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 445–450.
20. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007; 41: 326–331.
21. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11: 851–876.
22. Yanik M, Erel O, Kati M. The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatr. 2004; 16: 200–203.
23. Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001; 64: 43–51.
24. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007; 22: 67–73.
25. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinical depression. Psychosom Med 2006; 68: 1–7.
26. Owen AJ, Batterham MJ, Probst YC, Grenyer BF, Tapsell LC. Low plasma vitamin E levels in major depression: diet or disease? Eur J Clin Nutr 2005; 59: 304–306.
27. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003; 8: 365–370.
28. Homsi S, Federico F, Croci N et al. Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res 2009; 1291: 122–132.
29. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341–1345.
30. Laughren T Memorandum: overview for the December 13 meeting of Psychopharmacologic Drugs Advisory Committee. 2006.
31. Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev 2012; (11): CD004851.
32. US Food and Drug Administration. Relationship between psychotropic drugs and pediatric suicidality: review and evaluation of clinical data. 2004.
33. ADRAC. Use of SSRI antidepressants in children and adolescents. 2004.
34. Sicard P, Delemasure S, Korandji C et al. Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radic Res 2008; 42: 226–236.
35. Gomez-Garcia A, Martinez Torres G, Ortega-Pierres LE, Rodriguez-Ayala E, Alvarez-Aguilar C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev Esp Cardiol 2007; 60: 1242–1249.
36. Schupp N, Schmid U, Heidland A, Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. Atherosclerosis 2008; 199: 278–287.
37. Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh K Acad Geneeskd Belg 2008; 70: 193–219.
38. Habibi J, Whaley-Connell A, Qazi MA et al. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology 2007; 148: 2181–2188.
39. Ajith TA, Riji T, Anu V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin Exp Pharmacol Physiol 2008; 35: 625–629.
40. Ghanizadeh A, Hedayati A. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial. Depress Anxiety 2013; 30: 1084–1088.
41. Galecki P, Szemraj J, Bienkiewicz M, Zboralski K. Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 2009; 24: 277–286.
42. Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 520–527.
43. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389.
44. First MB, Spitzer RL, Gibbon M, Williams JBW Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), 1997.
45. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The Alcohol Use Disorders Identification Test (AUDIT): Guidelines for Use in Primary Care. Geneva: World Health Organization, 2001.
46. Australian Medicines Handbook. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd; 2015 [cited 4 Apr 2015]. Available from URL: https://amhonline.amh.net.au/auth. Australian Medicines Handbook Online.
47. Rush AJ, Trivedi MH, Ibrahim HM et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54: 573–583.
48. Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing Generalized Anxiety Disorder. Arch Intern Med 2006; 166: 1092–1097.
49. Guy W, ed. Clinical Global Impressions (CGI): ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, 1976.
50. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003; 189: 98–101.
51. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321–326.
52. Weissman MM, Prusoff BA, Thompson WD, Harding PS, Myers JK. Social adjustment by self-report in a community sample and in psychiatric outpatients. J Nerv Ment Dis 1978; 166: 317–326.
53. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000; 101: 323–329.
54. Livesley WJ, Jackson DN. Dimensional Assessment of Personality Pathology – Basic Questionnaire. Port Huron: SIGMA Assessment Systems, 2009.
55. Robichaud M, Dugas MJ. Negative problem orientation (Part I): psychometric properties of a new measure. Behav Res Ther 2004; 43: 391–401.
56. Ghaemi SN, Miller CJ, Berv DA, Klugman J, Rosenquist KJ, Pies RW. Sensitivity and specificity of a new bipolar spectrum diagnostic scale. J Affect Disord 2005; 84: 273–277.
57. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–435.
58. Reynolds WM. Suicidal Ideation Questionnaire: Professional Manual. Odessa, FL: Psychological Assessment Resources, 1988.
59. Posner K, Brown GK, Stanley B et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168: 1266–1277.
60. Hamer RM, Simpson PM. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry 2009; 166: 639–641.
61. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998; 317: 1309–1312.
62. Jo B, Ginexi E, Ialongo N. Handling missing data in randomized experiments with noncompliance. Prev Sci 2010; 11: 384–396.
63. MacKinnon DP. Introduction to Statistical Mediation Analysis. New York: Erlbaum, 2008.
64. Stafford L, Berk M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry 2011; 72: 1229–1235.
65. Therapeutic Goods Administration. Note for guidance on good clinical practice (CPMP/ICH/135/95 – Annotated with TGA comments); 2000. [Cited Cited 14/07/15.] Available from URL: https://www.tga.gov.au/sites/default/files/ich13595an.pdf
66. National Health and Medical Research Council. The national statement on ethical conduct in human research 2007 (Updated May 2015); 2015. [Cited 14/07/2015.] Available from URL: https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/e72_national_statement_may_2015_150514_a.pdf
67. Bortolasci CC, Vargas HO, Souza-Nogueira A et al. Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord 2014; 159: 23–30.
68. Newton-Howes G, Tyrer P, Johnson T et al. Influence of personality on the outcome of treatment in depression: a systematic review and meta-analysis. J Pers Disord 2014; 28: 577–593.
69. Akiskal H, Walker FR, Puzantian VR, King D, Rosenthal TL, Dranon M. Bipolar outcome in the course of depressive illness. Phenomenologic, familial, and pharmacologic predictors. J Affect Disord 1983; 5: 115–128.
70. Beesdo K, Höfler M, Leibenluft E, Lieb R, Bauer M, Pfennig A. Mood episodes and mood disorders: patterns of incidence and conversion in the first three decades of life. Bipolar Disord 2009; 11: 637–649.
71. Fiederowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 2011; 168: 40–48.